StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Deferred Income Tax Expense (Benefit) by Year

Deferred Income Tax Expense (Benefit) ($M) ($M)

AbbVie Deferred Income Tax Expense (Benefit): -$492M in FY2025, down 66.0% from a year earlier.

Latest, FY2025
-492
Period ended Dec 31, 2025
Change on a year earlier
-66.0%
-1,449 in FY2024
History
11 years
Since FY2015
Sources
9
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-20) ↗

Reported in Form 10-Q / 10-K Income Taxes Note & Cash Flows.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDeferred Income Tax Expense (Benefit) ($M) ($M)Year on yearSource
FY2025Dec 31, 2025-492-66.0%Form 10-K (filed 2026-02-20) ↗
FY2024Dec 31, 2024-1,449-49.8%Form 10-K (filed 2026-02-20) ↗
FY2023Dec 31, 2023-2,889+49.6%Form 10-K (filed 2026-02-20) ↗
FY2022Dec 31, 2022-1,931+115.0%Form 10-K (filed 2025-02-14) ↗
FY2021Dec 31, 2021-898-61.4%Form 10-K (filed 2024-02-20) ↗
FY2020Dec 31, 2020-2,325-2,005.7%Form 10-K (filed 2023-02-17) ↗
FY2019Dec 31, 2019122-108.0%Form 10-K (filed 2022-02-18) ↗
FY2018Dec 31, 2018-1,517-63.6%Form 10-K (filed 2021-02-19) ↗
FY2017Dec 31, 2017-4,162+422.9%Form 10-K (filed 2020-02-21) ↗
FY2016Dec 31, 2016-796-623.7%Form 10-K (filed 2019-02-27) ↗
FY2015Dec 31, 2015152–Form 10-K (filed 2018-02-16) ↗

Breakdown

What makes up deferred Income Tax Expense (Benefit)

Cite this data

StockData. (2026). AbbVie Deferred Income Tax Expense (Benefit) ($M), annual FY2015–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/tax-def-exp

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.